Interestingly, our results revealed that G6PDS188F variant, with reduced G6PD activity, prevented metabolic reprogramming, reduced 2-hydroxyglutatrate and fatty acid overload, and decreased the severity of NAFL. This evidence concerns the gene G6PD and non-alcoholic fatty liver.